X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
multiple sclerosis (9) 9
clinical neurology (8) 8
drug therapy (8) 8
index medicus (8) 8
multiple sclerosis, relapsing-remitting - drug therapy (8) 8
neurology (8) 8
adult (7) 7
female (7) 7
magnetic resonance imaging (7) 7
male (7) 7
treatment outcome (7) 7
middle aged (6) 6
clinical trials (5) 5
double-blind method (5) 5
young adult (4) 4
adolescent (3) 3
disability evaluation (3) 3
disease progression (3) 3
dose-response relationship, drug (3) 3
immune system (3) 3
immunosuppressive agents - therapeutic use (3) 3
medical colleges (3) 3
secondary prevention (3) 3
therapy (3) 3
analysis (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antibodies, monoclonal, humanized (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
care and treatment (2) 2
disease-activity (2) 2
double-blind (2) 2
drug administration schedule (2) 2
drug dosages (2) 2
europe (2) 2
fingolimod hydrochloride (2) 2
follow-up studies (2) 2
immunoglobulin g - administration & dosage (2) 2
immunoglobulin g - therapeutic use (2) 2
immunosuppressive agents - administration & dosage (2) 2
immunosuppressive agents - adverse effects (2) 2
injections, subcutaneous (2) 2
leukoencephalopathy, progressive multifocal - chemically induced (2) 2
leukoencephalopathy, progressive multifocal - diagnosis (2) 2
medical imaging equipment (2) 2
medical research (2) 2
medicine & public health (2) 2
medicine, general & internal (2) 2
multiple sclerosis, relapsing-remitting - pathology (2) 2
natalizumab (2) 2
neuroradiology (2) 2
neurosciences (2) 2
oral fingolimod (2) 2
patient monitoring equipment (2) 2
patient outcomes (2) 2
patient selection (2) 2
patients (2) 2
placebo-controlled trial (2) 2
practice guidelines as topic (2) 2
product development (2) 2
progressive multifocal leukoencephalopathy (2) 2
propylene glycols - adverse effects (2) 2
research (2) 2
sphingosine - adverse effects (2) 2
sphingosine - analogs & derivatives (2) 2
time factors (2) 2
abridged index medicus (1) 1
accurate (1) 1
acdf (1) 1
acquired-immunodeficiency-syndrome (1) 1
activation (1) 1
administration (1) 1
administration, oral (1) 1
age (1) 1
aged (1) 1
algorithms (1) 1
alpha-interferon (1) 1
animals (1) 1
antibodies (1) 1
antibodies, monoclonal (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
april (1) 1
autoimmune diseases (1) 1
autoimmune hepatitis (1) 1
b-cells (1) 1
baff (1) 1
beta -interferon (1) 1
blood-brain barrier (1) 1
brain (1) 1
brain - pathology (1) 1
brain atrophy (1) 1
cage placement (1) 1
cell-activating factor (1) 1
central-nervous-system (1) 1
cerebrospinal-fluid (1) 1
cervical spine (1) 1
cervical vertebrae - diagnostic imaging (1) 1
cervical vertebrae - surgery (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Neurology, The, ISSN 1474-4422, 2011, Volume 10, Issue 8, pp. 745 - 758
Journal Article
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2014, Volume 13, Issue 6, pp. 545 - 556
Journal Article
Journal Article
Lancet Neurology, ISSN 1474-4422, 2012, Volume 11, Issue 5, pp. 420 - 428
Journal Article
Journal Article
Journal of Neurology, ISSN 0340-5354, 2/2014, Volume 261, Issue 2, pp. 316 - 323
Journal Article
The Lancet Neurology, ISSN 1474-4422, 05/2012, Volume 11, Issue 5, p. 420
  Fingolimod 0·5 mg once daily is approved for treatment of relapsing multiple sclerosis (MS). In the phase 3, 2-year FREEDOMS (FTY720 Research Evaluating... 
Journal Article